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Abstract 
Purpose: To explore the modulatory effect of an Althaea officinalis root extract (AORE) on cisplatin-
induced cytotoxicity and cell proliferation in a lung cancer cell line. 
Methods: Aqueous AORE was obtained from peeled and powdered roots. The effect of cisplatin on 
cytotoxicity and cell proliferation was studied. The cisplatin concentrations tested ranged from 0 - 30 
mg/mL. Cell viability and proliferation were studied using trypan blue and MTT assays, respectively. The 
cells were also exposed to a combination of cisplatin and the AORE. 
Results: Cisplatin yielded a 50 % inhibitory concentration at 25 mg/mL and exhibited a dose-dependent 
cell proliferation loss. Combined use of the root extract and cisplatin had significant (R2 = 0.8305) 
modulatory effects on cytotoxicity and antiproliferative activities. The best inhibitory effects were 
observed in cells exposed to a combination of 8 or 10 % AORE and 25 mg/mL cisplatin. The optimal 
effect on cell proliferation was obtained using 25 mg/mL cisplatin and 10 % v/v AORE. 
Conclusion: The enhanced activity of cisplatin in combination with AORE was more pronounced for 
cell proliferation than cytotoxicity, indicating that AOREs may be used to control tumor progression and 
metastasis. 
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Althaea officinalis (AO), known as common 
marshmallow or marshmallow, belongs to the 
Malvaceae family within the order Malvales. This 
plant has perennial roots and stems that die in 
the autumn [1]. The Greek meaning of the 
generic name Althaea is “to cure” or “to heal,” 
signifying the beneficial application of this plant, 
especially its perennial roots [2]. Apart from the 
roots, the leaves, seeds, and flowers of the plant 
are used in traditional Chinese medicine [3,4]; 
major therapeutic applications of AO roots 
include treating ailments of the throat, mucous 
membranes, digestive system, and structures of 
the respiratory system, including the bronchial 
tubes [5]. AO extracts are known to have anti-
inflammatory, antimicrobial, anti-tussive, 
hypoglycaemic, and dermatological healing 
effects [6,7]. The leaves and roots are either 
applied topically as a paste or consumed directly. 
The roots of the plant are also used as a dried 
powder and as a vegetable. The most common 
preparation of this plant is marshmallow 
confectioneries, while the roots of AO are 
commonly used for their health effects. 
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The major phytochemicals identified in AO roots 
are mucilage with many polysaccharides, pectin, 
and tannins [8,9]. The mucilage content of AO 
varies between seasons, with maximum and 
minimum amounts present in winter and 
summer, respectively [10]. The pharmaceutical 
importance of AO has been extensively reviewed 
[11]. 
 
A549 is a human non-small cell lung 
adenocarcinoma cell line of the basal epithelial 
type. Having a doubling time of 22 – 24 h, this 
cell line is robust and well-suited for several in 
vitro applications.  
 
Cisplatin is a chemotherapeutic drug used 
extensively for cancer therapy, and it has been 
the drug of choice for several in vitro research 
applications. Cisplatin functions by inducing 
apoptosis via DNA cross-linking. 
 
The aim of this work was to determine the effect 
of AOR on the activity of cisplatin in A549 cells 





Plant material collection and extraction 
 
Collection of the AOR extract was performed in 
the winter of 2013, with the roots dried and 
peeled. A fine powder was obtained from the 
peeled roots by mechanical grinding and aliquots 
of 1 g were stored at -20 °C. A total of 1 g of fine 
powder was mixed in 10 mL of Milli-Q water at 4   
°C, filter-sterilized, and stored at -20 °C before 
being used for the experiments. The 
authentication of the plant identity and 
classification was performed by a taxonomist, Dr 
Hu Hong of Kunming Institute of Botany, Yunnan 
Province, China. A voucher specimen has been 
preserved at South China Botanical Garden 
Herbarium, Chinese Academy of Sciences 
(IBSC) with tTaxon Id #  20001368. 
 
Experimental design and cell cultures 
 
The entire study was performed in three steps, 
as follows: (1) ascertain the 50 % inhibitory 
concentration (IC50) value of cisplatin in A549 
cells, (2) ascertain the effect of direct exposure to 
an AOR extract on A549 cells, and (3) ascertain 
the modulatory effect of an AOR extract on 
cisplatin-induced cell inhibitory effects in the 
selected cell line. Healthy A549 cells from 85 % 
confluent T-25 flasks cultured in DMEM 
supplemented with 10 % FBS were used as a 
seed stock for all experiments. The seeding 
density of the cells used was 0.17 x 106 cells/mL 
in 24-well plates (1 mL cultures) and 1.0 × 105 
cells/well in 96-well plates (200 µL cultures). Cell 
viability and MTT assays were used as end 
points; cytotoxicity experiments were conducted 
in 24-well plates, and the MTT assay was 
performed in 96-well culture plates. For 
cytotoxicity assays, cells were collected along 
with the supernatant after mild mixing and 
attached cells were trypsinized, harvested, and 
pooled with the supernatants. Cells were washed 
once in medium without FBS and were analyzed 
for percent viability using the trypan blue assay. 
The MTT assay was performed on cells after the 
respective drug and combination (drug + AOR 
extract) exposures.  After exposure to the drug or 
the drug + AOR extract, the wells of 96-well 
plates were filled with 10 µL of MTT (stock: 10 
mg/mL) and incubated for 4 h. A total of 10 µL of 
solubilization buffer containing 10 % SDS and 
0.01 N HCl was added to the wells and the plates 
were incubated overnight at room temperature. 
The absorbance was measured at 550 nm using 
a microplate reader. All experiments were 
performed in triplicate; the average of the 
triplicate values were taken as the final values. 
 
Evaluation of cisplatin activity on A549 cells  
 
The IC50 value of cisplatin in A549 cells was 
determined by exposing cells to 10, 15, 20, 25, 
and 30 mg/mL cisplatin for 24 h. Similarly, cells 
in the 96-well plates were exposed to the same 
concentrations of the drug for 24 h and analyzed 
using the MTT assay.  
 
Evaluation of exposure of AOR extract on 
A549 cells 
 
AOR extract exposure was performed in 24- and 
96-well plates to explore the effects of the AOR 
extract on A549 cells. In addition, a 10 % stock 
extract was added to the cell culture wells to 
obtain a final concentration of 2, 4, 6, 8, and 10 
% of the stock. The cultures were incubated for 
24 h and analyzed by trypan blue and MTT 
assays, as described above.  
 
Determination of modulatory effect of the 
AOR extract on cisplatin-induced cytotoxicity 
in A549 cells 
 
Cells in 24- and 96-well plates were 
simultaneously exposed to cisplatin at the IC50 
concentration and 2, 4, 6, 8, and 10 % AOR 
extract (as in step 2). The cultures were 
incubated for 24 h and analyzed by trypan blue 
and MTT assays, as described above. 
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A one-way analysis of variance was used to 
analyze the variables. Standard deviation was 







Healthy cells did not show any change in 
morphology when exposed to the AOR extract. 
However, morphological changes were observed 
for cells exposed to cisplatin and a combination 
of 25 mg/mL cisplatin + 10 % v/v AOR extract 
(Figure 1). 
 
Effect of cisplatin on A549 cell viability 
 
The viability of untreated A549 cells was 96 % 
while the values for cisplatin at concentrations of 
0, 0.25, 5, 10, 15, 20, 25, and 30 mg/mL were 
96, 92, 81, 72, 63, 56, 52, and 49 %, 
respectively. The IC50 value of cisplatin was 
close to 25 mg/mL (Figure 2a). 
 
Cytotoxicity and cell proliferation  
 
The absorbance value for the control was 0.73 
while it was 0.64, 0.61, 0.58, 0.52, 0.47, 0.32, 
and 0.26 for the seven different cisplatin 
concentrations, respectively (Figure 2b). 
 
Cell viability after exposure to AOR extract 
 
There was no significant effect of direct exposure 
to the AOR extract on A549 cells. However, a 
marginal decrease in viability was observed in 
cells exposed to 8 and 10 % AOR stock extract 
with 94 % viability (Figure 3). 
 
The MTT assay did not show any significant 
effect on cell proliferation, with absorbance 





Figure 1: Panels show A549 cells in their normal healthy condition and after exposure to cisplatin, the AOR 
extract, or a combination of the AOR extract + cisplatin. Panels 1a and c show control cells and those exposed to 
the AOR extract respectively. Panel 1b shows cells exposed to 30 mg/mL of cisplatin, which is close to the IC50 
value. Panel 1d shows cells exposed to a combination of 25 mg/mL (IC50) cisplatin + 10 % AOR extract, which 
induced a maximum inhibitory effect with minimal cell viability 
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Figure 2: Panel 2a shows the IC50 value of cisplatin (approximately 27 mg/mL). Panel 2b shows the dose 
response of cisplatin exposure in reducing the proliferation of A549 cells 
 
 
Figure 3:  The AOR extract did not have any significant effect on cell viability, suggesting that the extract did not 
have any toxic effects on the cells 
 
Effect of AOR extract on cisplatin-induced 
cytotoxicity in A549 cells 
 
The cells exposed to 25 mg/mL (IC50) cisplatin 
and 2, 4, 6, 8, and 10 % AO stock extract 
produced viability values of 51, 51, 41, 41, and 
39 %, respectively. While the 2 and 4 % AOR 
stock extracts did not have any significant 
cytotoxicity-enhancing effect, there was a 
significant increase in cytotoxicity (increased IC50 
value of cisplatin) in cultures exposed to 8 and 




The absorbance values for cells exposed to 25 
mg/mL cisplatin and 0, 2, 4, 6, 8, and 10 % AOR 
stock extract were 0.31, 0.3, 0.3, 0.23, 0.21, and 




Figure 4:  Effect of AOR extract on cisplatin-induced anti-proliferation and toxicity in A549 cells. Panels 4a and b 
show a synergistic effect on proliferation and toxicity, respectively. The IC50 values of cisplatin decreased in the 
presence of the AOR extract compared to the IC50 of cisplatin exposure in isolation 
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Figure 5:  Supplementation with 8 or 10 % v/v of the AOR extract along with cisplatin at the IC50 concentration 
(25 mg/mL) increased cytotoxicity significantly. A standard deviation of 41 and 39 for AOR extract 
supplementation with 6, 8, and 10 % v/v was obtained, indicative of a positive modulatory effect of the extract on 
cisplatin-induced effects in the cell line 
 
 
Figure 6: The AOR extract had significant synergistic effects at 8 and 10 % v/v on cisplatin-induced anti-
proliferative activity. The standard deviation for AOR extract supplementation at 6, 8, and 10 % v/v was 0.23, 




The cell line (A549) and drug (cisplatin) used in 
this study are considered useful materials based 
on several previous studies. AOR extracts are 
also commonly used in traditional medicine; the 
past decade has seen a growing number of 
scientific reports of studies performed 
systematically using AOR extracts. The AOR 
extract in this study was used in combination with 
cisplatin to study its modulatory effects on two 
parameters: cytotoxicity and anti-proliferation. 
While cytotoxicity is an effect of immediate and 
direct consequence, cell proliferation involves a 
sequence of events. However, both parameters 
have relevance to cancer research in terms of 
killing cancer cells and limiting metastasis. The 
AOR extract did not induce changes in the 
morphology, viability, or proliferation of A549 
cells, suggesting that it is safe for cells. The 
extract had marked modulatory effects on 
cisplatin-induced toxicity and an anti-proliferative 
effect at 8 and 10 % v/v. The synergistic effect 
was significant; it induced marked morphologic 
changes with a reciprocal loss in viability. A 
combination of 25 mg/mL cisplatin + 10 % v/v 
AOR extract induced more pronounced anti-





The findings of this study indicate the usefulness 
of AOR extract in modulating the effect of 
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cisplatin in A549 cells in terms of cytotoxicity and 
cell proliferation. The modulatory effect on cell 
proliferation was greater than the effect on 
cytotoxicity, demonstrating that AOR extract is a 
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